Table 2 Clinical information of KHP PCaBB participants from Jan 2013-Dec 2015
From: King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)
Clinical Variable | Consented (n = 549) |
|---|---|
Treatment type | |
Surgery | 357 (65.0) |
Active Monitoring | 74 (13.5) |
Anti-cancer drug regimen (Hormone Therapy) | 98 (17.9) |
Anti-cancer drug regimen (Cytotoxic Chemotherapy) | 2 (0.4) |
Brachytherapy | 18 (3.3) |
Specialist palliative care | 0 (0.0) |
Mean PSA (SD) at diagnosis (μg/L) | 42.77 (±374.927) |
Gleason Score | |
6 | 74 (13.5) |
7 | 358 (65.2) |
8 | 44 (8.0) |
9 | 53 (9.7) |
10 | 3 (0.5) |
Unrecorded | 19 (3.5) |
Gleason Group | |
Grade 1 | 74 (13.5) |
Grade 2 | 247 (45.0) |
Grade 3 | 111 (20.2) |
Grade 4 | 44 (8.0) |
Grade 5 | 56 (10.2) |
T stage | |
TX | 42 (7.7) |
T0 | 28 (5.1) |
T1 | 4 (0.7) |
T1a | 2 (0.4) |
T1b | 0 (0.0) |
T1c | 16 (2.9) |
T2 | 106 (19.3) |
T2a | 153 (27.9) |
T2b | 15 (2.7) |
T2c | 60 (10.9) |
T3 | 17 (3.1) |
T3a | 69 (12.6) |
T3b | 34 (6.2) |
T4 | 3 (0.5) |
T4a | 0 (0.0) |
N stage | |
NX | 191 (34.8) |
N0 | 334 (60.8) |
N1 | 24 (4.4) |
N2 | 0 (0.0) |
M stage | |
MX | 221 (40.3) |
M0 | 315 (57.4) |
M1 | 5 (0.9) |
M1a | 1 (0.2) |
M1b | 5 (0.9) |
M1c | 2 (0.4) |
Risk Category | |
Localised prostate cancer | |
Low risk | 83 (15.1) |
Intermediate risk | 252 (45.9) |
High Risk | 157 (28.6) |
Regionally metastatic/ Locally advanced | 23 (4.2) |
Distant metastasis | 25 (4.6) |
Unrecorded | 9 (1.6) |
Comorbidities | |
Mean number of comorbidities (SD) | 1.9 (±2.021) |
Previous/other cancer | 20 (3.6) |
Cardiovascular disease | 218 (39.7) |
HIV or Infectious Diseases | 5 (0.9) |
Hyperlipidaemia and hypercholesterolemia | 87 (4.8) |
Diabetes | 68 (3.8) |
Psychological | 32 (5.8) |
Mean number of medications (SD) | 2.213 (±2.529) |
Erectile dysfunction medication | 216 (39.3) |
Outcome | |
Disease stable | 444 (80.9) |
Discharged to GP | 56 (10.2) |
Treatment discharged to GP | 17 (3.1) |
Discharged to different hospital | 4 (0.7) |
Progression | 7 (1.3) |
Progression to metastasis | 3 (0.5) |
Recurrence | 2 (0.4) |
Death | 6 (1.1) |
Awaiting treatment | 2 (0.4) |
Refused further treatment | 1 (0.2) |
Treated privately | 1 (0.2) |
Lost to follow up | 6 (1.1) |
Involvement in clinical trial | 34 (6.2) |